Pharma exports to UK near $1 bn as CETA opens door to tariff-free trade

By: Team India Tracker

The trade pacts with Australia, the UAE and the UK mark a departure from the cautious approach that shaped much of the previous decade

Trade agreements are often judged by the number of tariffs they remove or the size of the market they open. That is an understandable metric, but it rarely captures the larger story. The India-UK Comprehensive Economic and Trade Agreement (CETA), which is expected to push India's pharmaceutical exports to Britain close to the $1 billion mark in FY27, deserves to be viewed through a wider lens. Its real significance lies less in the immediate boost to exports than in what it says about India's evolving place in the global pharmaceutical industry. 

The projected increase in exports—from about $903 million in FY26 to nearly $1 billion this year—is certainly welcome. Removing tariffs on almost all pharmaceutical products gives Indian manufacturers an immediate price advantage in one of Europe’s largest healthcare markets. At a time when growth in many advanced economies is slowing and global trade is becoming increasingly fragmented, any agreement that expands market access is valuable. 

But tariffs are only one part of the equation. 

The United Kingdom is not merely another export destination. It is one of the world’s most demanding pharmaceutical markets, governed by rigorous quality, safety and regulatory standards. For Indian companies, succeeding in Britain is as much about earning credibility as it is about increasing sales. Every regulatory approval, every successful supply contract and every long-term partnership strengthens the perception that Indian manufacturers can compete not only on price but also on quality and reliability. 

That distinction matters because India's pharmaceutical industry is itself at an inflection point. For decades, its comparative advantage rested on producing low-cost generic medicines. The strategy transformed the country into what is often described as the “pharmacy of the developing world.” India today supplies roughly one-fifth of the world's generic medicines by volume. Yet the next phase of growth cannot depend solely on being the cheapest producer. 

Margins in generic drugs have been shrinking across global markets. Regulatory scrutiny has intensified. Compliance costs have risen sharply. Large buyers, particularly in developed economies, are demanding not just affordability but supply-chain resilience, manufacturing consistency and stringent quality control. In other words, the industry is moving up the value chain, and Indian companies must move with it. 

The UK agreement arrives at precisely this moment. 

Equally important is the changing geography of India’s pharmaceutical exports. The US remains the industry’s largest overseas market, accounting for a substantial share of export revenues. But dependence on a single market has become increasingly risky. Pricing pressure in the US has intensified, regulatory inspections have become more demanding, and policy uncertainty has grown as healthcare costs become a political issue. Any company with a diversified export portfolio is inherently better placed to absorb such shocks. 

Britain offers that diversification. It may not rival the US in absolute market size, but it provides stability, purchasing power and access to sophisticated healthcare institutions. Success there can also serve as a gateway into wider European markets, particularly if India eventually concludes a comprehensive trade agreement with the European Union. 

There is another lesson embedded in this story. Trade agreements increasingly determine competitiveness as much as manufacturing efficiency does. Two companies producing identical medicines at similar costs can end up with very different outcomes if one enjoys tariff-free access while the other does not. In that sense, diplomacy has become an extension of industrial policy. 

India has recognised this reality rather late but appears determined to catch up. Recent trade agreements with countries such as Australia and the UAE, followed by the UK pact, suggest a shift away from the caution that characterised its trade policy for much of the previous decade. Negotiations with the European Union and the US are also progressing, even if not without difficulty. 

However, trade agreements create opportunities; they do not guarantee success. 

Indian pharmaceutical companies will still have to invest heavily in research, manufacturing technology, regulatory compliance and product development. Future growth is likely to come less from traditional generics and more from complex generics, biosimilars and speciality medicines, where entry barriers are higher but so are margins. Companies that continue to rely exclusively on low-cost production may find the competitive advantage narrowing over time. 

For policymakers, the lesson is equally straightforward. Export competitiveness cannot be sustained by trade agreements alone. Efficient ports, reliable logistics, predictable regulation and faster approvals matter just as much as tariff concessions. Industrial policy and trade policy have to work together if India wants to become a genuine pharmaceutical powerhouse. 

Crossing the $1 billion export milestone to Britain will undoubtedly be a symbolic achievement. Yet symbols matter only when they represent a deeper structural shift. If Indian pharmaceutical companies use this opening to diversify markets, move up the value chain and strengthen their global reputation, the UK agreement will be remembered not as a tariff-cutting exercise but as another step in India’s journey from being the world’s pharmacy to becoming one of its most trusted healthcare partners.